CE
CERT.US Certara Inc
- Market cap
- USD 1.76B
- P/E
- -
- P/B
- 1.86x
- ROE
- -8.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is CERT.US undervalued?
Graham numberThe Graham number of Certara Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Certara Inc fundamental analysis
No fundamental analysis for Certara Inc yet.
Certara Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Certara Inc
Certara, Inc., together with its subsidiaries, provides technology-driven services and software products for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the Americas, Europe, the Middle East, Africa, and Asia Pacific. It offers model-informed drug development solutions; biosimulation solutions to predict pharmacokinetics and pharmacodynamics; Simcyp simulator, a mechanistic biosimulation platform for physio…
Full company profileCertara Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Certara Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | 164M | 209M | 244M | 286M | 336M | 354M | 385M | 419M | 393M |
| Gross Profit | 92.7M | 129M | 143M | 174M | 203M | 213M | 231M | 258M | 230M |
| Operating Income | -4.65M | 19.6M | -24.4M | 13.6M | 32.5M | -40.8M | -1.73M | 21.0M | 8.10M |
| EBITDA | 32.3M | 60.4M | 17.9M | 58.6M | 89.0M | 23.8M | 72.4M | 103M | 64.2M |
| Net Income | -33.3M | -8.93M | -49.4M | -13.3M | 14.7M | -55.4M | -12.1M | -1.60M | -77.9M |
| EPS | -0.25 | -0.06 | -0.32 | -0.09 | 0.09 | -0.35 | -0.08 | -0.01 | -0.51 |
| Balance Sheet | |||||||||
| Total Assets | 1.05B | 1.04B | 1.27B | 1.51B | 1.57B | 1.56B | 1.58B | 1.56B | 1.41B |
| Total Liabilities | 559M | 545M | 447M | 470M | 493M | 516M | 516M | 494M | 437M |
| Shareholders' Equity | 493M | 492M | 822M | 1.04B | 1.08B | 1.05B | 1.06B | 1.06B | 978M |
| Cash & Short-term Investments | 11.7M | 29.3M | 271M | 186M | 237M | 235M | 179M | 189M | 215M |
| Total Debt | 408M | 401M | 299M | 308M | 308M | 303M | 312M | 11.4M | 298M |
| Cash Flow | |||||||||
| Operating Cash Flow | 11.6M | 38.0M | 44.8M | 60.4M | 92.5M | 82.8M | 80.5M | 96.3M | 69.9M |
| Capital Expenditure | 11.5M | 9.52M | 7.94M | 8.90M | 12.5M | 15.3M | 21.0M | 26.6M | 20.9M |
| Free Cash Flow | 107K | 28.5M | 36.9M | 51.5M | 80.0M | 67.4M | 59.4M | 69.8M | 49.0M |
| Ratios | |||||||||
| ROE | -6.7% | -1.8% | -6.0% | -1.3% | 1.4% | -5.3% | -1.1% | -0.2% | -8.0% |
| ROA | -3.2% | -0.9% | -3.9% | -0.9% | 0.9% | -3.5% | -0.8% | -0.1% | -5.5% |
| Net Profit Margin | -20.3% | -4.3% | -20.3% | -4.6% | 4.4% | -15.6% | -3.1% | -0.4% | -19.8% |
| Debt to Equity | 0.83x | 0.82x | 0.36x | 0.30x | 0.29x | 0.29x | 0.29x | 0.01x | 0.30x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Certara Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | USD 272K | 0.00 | - |
| 2020 | USD 19.9M | 0.13 | - |
| 2019 | USD 703K | 0.00 | - |
| 2018 | USD 75.0M | 0.57 | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Certara Inc
- Insiders 3.59%
- Institutions 96.42%
- Public & others 0.00%
- Shares outstanding 153M
- Free float 112M
Top funds holding CERT.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| iShares Core S&P Small-Cap ETF | 6.78M | 4.45% | -0.26% | Oct 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 3.10M | 2.03% | -16.79% | Sep 2026 |
| iShares Russell 2000 ETF | 3.00M | 1.97% | 0.00% | Oct 2026 |
| DFA U.S. Small Cap Value I | 2.93M | 1.92% | +43.24% | Sep 2026 |
| Vanguard Small Cap Index | 2.40M | 1.58% | -10.25% | Sep 2026 |
| Wasatch Small Cap Value | 2.10M | 1.37% | +15.59% | Sep 2026 |
| T. Rowe Price Small-Cap Value | 1.63M | 1.07% | +14.37% | Sep 2026 |
| Vanguard MStar Small Cap Value Index | 1.56M | 1.03% | -8.23% | Sep 2026 |
| Columbia Small Cap Value Discv A | 1.30M | 0.85% | +0.73% | Sep 2026 |
| Fidelity Small Cap Index | 1.29M | 0.84% | +1.21% | Aug 2026 |
| DFA U.S. Targeted Value I | 1.18M | 0.77% | 0.00% | Sep 2026 |
| iShares Russell 2000 Value ETF | 1.11M | 0.73% | 0.00% | Oct 2026 |
| Royce Micro-Cap Trust | 1.08M | 0.71% | 0.00% | Sep 2026 |
| State Street SPDR Port S&P 600 Sm CpETF | 1.03M | 0.67% | -0.05% | Oct 2026 |
| Dimensional US Small Cap Value ETF | 885K | 0.58% | 0.00% | Sep 2026 |
| Dimensional US Targeted Value ETF | 861K | 0.56% | 0.00% | Oct 2026 |
| First Eagle Small Cap Opportunity I | 833K | 0.55% | +0.58% | Sep 2026 |
| Vanguard Tax-Managed Small Cap Adm | 828K | 0.54% | 0.00% | Sep 2026 |
| Column Small Cap Select | 776K | 0.51% | +300.22% | Sep 2026 |
| Vanguard Russell 2000 ETF | 685K | 0.45% | +2.62% | Sep 2026 |
Top institutions holding CERT.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| BlackRock Inc | 18.8M | 12.34% | +31.52% | Jun 2026 |
| Deerfield Management Co | 7.51M | 4.93% | -3.79% | Jun 2026 |
| Haveli Investment Management LLC | 7.40M | 4.85% | 0.00% | Jun 2026 |
| Jefferies Financial Group Inc | 7.09M | 4.65% | +3.40% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 7.06M | 4.63% | +18.21% | Jun 2026 |
| Dimensional Fund Advisors, Inc. | 6.48M | 4.25% | +7.59% | Sep 2026 |
| Vanguard Capital Management, LLC | 5.28M | 3.46% | -1.44% | Jun 2026 |
| State Street Corp | 4.82M | 3.16% | +22.37% | Jun 2026 |
| Wasatch Advisors LP | 4.30M | 2.82% | -18.46% | Jun 2026 |
| Geode Capital Management, LLC | 3.14M | 2.06% | +48.57% | Jun 2026 |
| Royce & Associates, LP | 2.76M | 1.81% | +126.82% | Jun 2026 |
| UBS Group AG | 2.67M | 1.75% | -22.05% | Jun 2026 |
| Millennium Management LLC | 2.56M | 1.68% | +103.44% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 2.55M | 1.67% | -21.27% | Jun 2026 |
| First Trust Advisors L.P. | 2.42M | 1.59% | +164.80% | Jun 2026 |
| AQR Capital Management LLC | 2.16M | 1.42% | +278.49% | Jun 2026 |
| Ameriprise Financial Inc | 2.03M | 1.33% | -9.65% | Jun 2026 |
| T. Rowe Price Investment Management,Inc. | 2.00M | 1.31% | +49.40% | Jun 2026 |
| Systematic Financial Management LP | 1.89M | 1.24% | 0.00% | Jun 2026 |
| Bank of America Corp | 1.80M | 1.18% | -11.97% | Jun 2026 |
Certara Inc company profile
- Company name
- Certara Inc
- Ticker
- CERT.US
- Exchange
- USA Stocks
- Listed since
- Dec 11, 2020
- Sector
- Healthcare
- Industry
- Health Care Technology
- Employees
- 1,515
- Fiscal year end
- December
- Address
- 4 Radnor Corporate Center, Radnor, PA, United States, 19087
- Phone
- 415 237 8272
- Website
- certara.com
About Certara Inc
Certara, Inc., together with its subsidiaries, provides technology-driven services and software products for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the Americas, Europe, the Middle East, Africa, and Asia Pacific. It offers model-informed drug development solutions; biosimulation solutions to predict pharmacokinetics and pharmacodynamics; Simcyp simulator, a mechanistic biosimulation platform for physiologically based pharmacokinetic simulation; Simcyp Discovery for scientists working on pre-investigational new drug and translational stages; Simcyp Biopharmaceutics for formulation scientists; and Simcyp Secondary Intelligence that integrates toxicology with quantitative analysis of large networks of molecular and functional biological changes. It also provides Phoenix WinNonlin, a platform for non-compartmental analysis; Phoenix cloud that offers a secured and validated Certara Amazon Web Services workspace; Phoenix NLME, a population modeling and simulation software; and Pirana Modeling Workbench, which provides modelers with a structure to facilitate the iterative processes. In addition, it offers Chemaxon JChem engines, a chemical search engine; Chemaxon Compound Registration that supports a streamlined lead optimization process workflow; Chemaxon Design Hub, a design and tracking platform; Certara D360 software, a scientific informatics system; and Chemaxon Marvin, a chemical drawing tool. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange to define data standards and specifications; Metadata Repository that enables study design using controlled and standardized data; CoAuthor software, which creates and writes regulatory submissions and medical publications; and GlobalSubmit, a submissions management software. Certara Inc. was founded in 2008 and is headquartered in Radnor, Pennsylvania.
Certara Inc management
9- Mr. Leif E. PedersenSenior Advisor · born 1965
- Mr. Jon ResnickCEO & Director · born 1973
- Mr. Julien PerrierPresident & Chief Commercial Officer
- Mr. Faiz MohammedInterim CFO, Senior VP of Finance, Treasurer and Principal Financial & Accounting Officer · born 1973
- Dr. Christopher Bouton Ph.D.Chief Technology Officer & Chief AI Officer
- Eric JahnChief Information Officer
- Mr. Daniel D. CorcoranSenior VP, General Counsel & Secretary · born 1967
- Mr. Ron DiSantisSenior Vice President of Corporate Development
- Ms. Rona S. AnhaltChief Human Resources Officer · born 1965